Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

ABSTRACT:

Background

Current pulmonary hypertension treatment guidelines recommend use of a risk stratification model encompassing a range of parameters, allowing patients to be categorised as low, intermediate or high risk. Three abbreviated versions of this risk stratification model were previously evaluated in patients with pulmonary arterial hypertension (PAH) in the French, Swedish and COMPERA registries. Our objective was to investigate the three abbreviated risk stratification methods for patients with mostly prevalent PAH and chronic thromboembolic pulmonary hypertension (CTEPH), in patients from the PATENT-1/2 and CHEST-1/2 studies of riociguat.

Methods

Risk was assessed at baseline and at follow-up in PATENT-1 and CHEST-1. Survival and clinical worsening-free survival were a

SUBMITTER: Humbert M 

PROVIDER: S-EPMC6551213 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature